undamentalytics Newsletter
Sign in

Celldex Therapeutics, Inc. cash flow statement

In fiscal 2025, Celldex Therapeutics, Inc.'s operations generated −$211m of cash; it spent $2.7m on capital projects, leaving free cash flow of −$214m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−30−30−36−50−68−102−99−113−100−75−46−40−61−104−107−158−211−236
Depreciation and amortisation332222334454333333
Stock-based pay33225713151285491624343635
Capital spending121042532112122237
Free cash flow−30−32−36−50−72−103−104−116−102−76−47−42−62−106−109−160−214−242
Free cash flow after stock pay−33−35−39−52−76−110−117−131−114−84−52−46−71−121−133−194−250−277
Shares issued113684296—18914512916171270—216432——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CLDX vs CLNNCLDX vs IBIOCLDX vs LSTAAIM vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Celldex Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Celldex Therapeutics, Inc.